Code is covered without prior authorization (high confidence)
Medicare Pricing
Work RVU
6.53
Facility
$329.67
Non-Facility
$329.67
Documentation Required
Operative reports detailing the cytoreductive surgery, HIPEC technique (open vs closed), chemotherapeutic agent(s) used, doses, perfusate temperature(s) (inflow/outflow), perfusion duration, and intra-operative temperature monitoring logs (target intra‑abdominal/intratumoral temperatures often 41–43°C; some studies aimed for tumor temperature ≥42.5°C for specified durations).
Intra‑operative and peri‑operative monitoring records including hemodynamics, laboratory values, transfusions, and post-operative complications (with grading), and length of hospital stay.
Documentation of informed consent including discussion of investigational/experimental status where applicable, expected benefits, potential risks and morbidity, and alternative standard-of-care therapies.
Evidence that treatment is being provided in a center with appropriate specialized equipment and trained personnel (documentation of center expertise, temperature monitoring capability, and post-operative care resources) when required by guideline recommendations.
Key Coverage Criteria
CPT 96548 Intraoperative HIPEC, each additional 30 minutes — covered if selection criteria are met.
Selected patients with peritoneal metastases from small bowel adenocarcinoma — CRS + HIPEC may offer survival benefit in highly selected patients (systematic review data).
Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of pseudomyxoma peritonei (including disseminated peritoneal adenomucinosis (DPAM) ... as well as peritoneal mucinous carcinomatosis).
Cytoreductive surgery combined with HIPEC for the treatment of peritoneal mesothelioma.
Cytoreductive surgery combined with HIPEC for the treatment of goblet cell carcinoid tumor.
HIPEC for use with cisplatin at the time of interval debulking surgery for FIGO stage III ovarian cancer.
Ask Verity about documentation requirements, denial risks, or coverage in your state.
Follow-up documentation including response assessments, disease‑free/overall survival measures, and reporting of adverse events and late toxicity (to support continued evaluation if performed as part of a study or registry).
No explicit 'Documentation Requirements' section is present in this text. Inferred/documentation items commonly referenced in the literature and that would be expected to support medical necessity include: